Realm Therapeutics CEO to present at 2017 Bio Investor Forum
Biopharma group Realm Therapeutics's chief executive officer will present an update on the firm's two lead drug development programmes at the 2017 BIO Investor Forum in California.
Health Care Equipment & Services
11,713.81
16:59 26/04/24
Realm Therapeutics
11.50p
16:59 26/03/19
The forum, to be held at the Westin St Francis Hotel in San Francisco on Wednesday, is slated to feature presentations from the heads of several leading pharmaceutical brands and an address from Realm's CEO Alex Martin.
Martin said he would discuss the company's two leading drug development programmes, PR022 for Atopic Dermatitis and PR013 for allergic conjunctivitis, as well as Realm's recent £19.3m fundraising made via a private placement with new and existing investors in the US and the UK that was aimed at advancing the aforementioned products, as well as paying for the group to conduct a Phase II proof of concept study in acne vulgaris.
As of 0830 BST, shares were unmoved at 34.50p.